Search results
-
ESMO 2025 movers – FDA volte-face to the rescue
ESMO 2025 movers – FDA volte-face to the rescue … in four key studies presented at ESMO. Selected ESMO 2025 risers Company Share movement* … to head against AbbVie’s Elahere . Selected ESMO 2025 fallers Company Share movement* …
- 10/23/2025 - 13:33 -
ESMO 2025 – Sanofi takes aim at Lutathera
ESMO 2025 – Sanofi takes aim at Lutathera … 35% Note: data cutoff 14 Apr 2025. Source: ESMO 2025. Discussing the data in …
- 10/22/2025 - 16:50 -
ESMO 2025 – bemarituzumab fails to convince
ESMO 2025 – bemarituzumab fails to convince …
- 10/24/2025 - 10:55 -
ESMO 2025 – Incyte impresses in KRAS G12D
ESMO 2025 – Incyte impresses in KRAS G12D … KRAS G12D inhibitors in pancreatic cancer at ESMO 2025 INCB161734 HRS-4642 HRS-4642 … & unconfirmed responses; **confirmed responses. Source: ESMO 2025. Conferences Trial …
- 10/22/2025 - 16:25 -
ESMO 2025 – Merck and Daiichi Rejoice over raludotatug
ESMO 2025 – Merck and Daiichi Rejoice over raludotatug … . Source: Dr Isabelle Ray-Coquard & ESMO 2025. Conferences Trial …
- 10/20/2025 - 13:12 -
ESMO 2025 – little solace for Roche’s doomed TIGIT
ESMO 2025 – little solace for Roche’s doomed TIGIT …
- 10/21/2025 - 08:07 -
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
ESMO 2025 – no starring role for Exelixis’s Cabometyx … (95% CI 0.65-0.94) Source: Dr Anwaar Saeed & ESMO 2025. On the question of whether zanzalintinib …
- 10/21/2025 - 13:55 -
ESMO 2025 – more ivonescimab shots on goal for Summit
ESMO 2025 – more ivonescimab shots on goal for Summit …
- 10/21/2025 - 15:21 -
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
ESMO 2025 – Novartis looks for Pluvicto prostate Addition …
- 10/20/2025 - 12:52 -
ESMO 2025 – Merck shoots for an ovarian cancer first
ESMO 2025 – Merck shoots for an ovarian cancer first …
- 10/20/2025 - 12:51
